2m 2m 2m 2m 2m 2m 2m
VIRIDIAN THERAPT (VRDN)
NASDAQ
$17.59-$0.04 (-0.26%)
Price as of Jun 23, 2026 5:11 PM EDT- $1.9BMarket Cap
- 19.85%1-Year Change
- BiotechnologyIndustry
VIRIDIAN THERAPT (VRDN)
$17.59-$0.04 (-0.26%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 70.0M +23,078.81% | 302,000 -3.82% | 314,000 -82.28% | 1.8M -40.20% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 70.0M +23,078.81% | 302,000 -3.82% | 314,000 -82.28% | 1.8M -40.20% | |
Sales and Marketing Expense | 95.3M N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -338.9M +42.26% | -238.3M +49.13% | -159.8M +58.35% | -100.9M +77.36% | |
Depreciation and Amortization Expense | 460,000 -14.81% | 540,000 +3.45% | 522,000 +104.71% | 255,000 +112.50% | |
Total Operating Expenses | 434.2M +45.07% | 299.3M +17.50% | 254.8M +87.22% | 136.1M +64.56% | |
Operating Profit | -363.4M +21.52% | -299.0M +17.52% | -254.4M +89.46% | -134.3M +68.45% | |
Interest Income | 27.4M -14.73% | 32.1M +73.10% | 18.6M +277.60% | 4.9M N/A | |
Interest Expense | N/A N/A | N/A N/A | -1.3M +160.00% | -500,000 N/A | |
Interest Income and Expense and Net | 27.4M -14.73% | 32.1M +86.13% | 17.3M +290.92% | 4.4M N/A | |
Total Nonoperating Income and Expense | 20.8M -28.51% | 29.1M +74.00% | 16.7M +277.34% | 4.4M +1,293.08% | |
Income before Taxes | -363.4M +21.52% | -299.0M +17.52% | -254.4M +89.46% | -134.3M +69.12% | |
Income Taxes | 0 N/A | N/A N/A | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -342.6M +26.91% | -269.9M +13.55% | -237.7M +83.05% | -129.9M +63.54% | |
Net Income from Continuing Operations Applicable to Common | -342.6M +26.91% | -269.9M +13.55% | -237.7M +83.05% | -129.9M +63.54% | |
Basic EPS and Net Income | -3.32 +8.14% | -3.07 -42.18% | -5.31 +31.11% | -4.05 -39.19% | |
Diluted EPS and Net Income | -3.32 +8.14% | -3.07 -42.18% | -5.31 +31.11% | -4.05 -39.19% | |
Basic Weighted Average Shares | 84.8M +24.92% | 67.9M +51.68% | 44.8M +39.48% | 32.1M +169.22% | |
Diluted Weighted Average Shares | 84.8M +24.92% | 67.9M +51.68% | 44.8M +39.48% | 32.1M +169.22% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 212.4M +113.25% | 99.6M -3.14% | 102.8M -33.91% | 155.6M +267.81% | |
Short-Term Investments | 662.3M +7.17% | 618.0M +65.00% | 374.5M +39.25% | 269.0M +73.90% | |
Cash and Cash Equivalents and Short-Term Investments | 874.7M +21.89% | 717.6M +50.32% | 477.4M +12.44% | 424.6M +115.55% | |
Total Current Assets | 894.2M +21.09% | 738.5M +51.80% | 486.5M +12.83% | 431.2M +115.41% | |
Accumulated Depreciation | 1.2M -3.95% | 1.3M +20.69% | 1.0M -47.65% | 2.0M +12.84% | |
Property and Plant and Equipment and Net | 1.2M -0.65% | 1.2M -26.08% | 1.7M +26.09% | 1.3M +253.60% | |
Total Long-Term Assets | 1.5M +206.59% | 501,000 -17.05% | 604,000 -38.49% | 982,000 -34.14% | |
Total Assets | 899.4M +21.15% | 742.4M +51.38% | 490.4M +12.72% | 435.1M +113.58% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 70.7M +47.67% | 47.9M +79.74% | 26.6M -20.13% | 33.3M +144.57% | |
Total Long-Term Debt | 84.2M +309.02% | 20.6M +1.87% | 20.2M +334.98% | 4.6M N/A | |
Total Long-Term Liabilities | 2.3M +15.66% | 2.0M +104.65% | 989,000 -15.61% | 1.2M -2.98% | |
Total Liabilities | 177.3M +150.48% | 70.8M +46.20% | 48.4M +20.92% | 40.0M +150.28% | |
Retained Earnings | -1.3B +34.40% | -995.9M +37.19% | -725.9M +48.70% | -488.2M +36.25% | |
Total Stockholders Equity | 722.2M +7.52% | 671.6M +51.95% | 442.0M +11.89% | 395.1M +110.46% | |
Total Shares Outstanding | 101.8M +25.72% | 81.0M +50.03% | 54.0M +30.70% | 41.3M +72.65% | |
Cash Flow | |||||
Cash from Operating Activities | -276.4M +18.97% | -232.3M +26.14% | -184.2M +96.26% | -93.8M +71.92% | |
Capital Expenditures | 495,000 -3.13% | 511,000 -43.10% | 898,000 +12.67% | 797,000 +135.80% | |
Cash from Investing Activities | -37.6M -83.57% | -228.7M +142.60% | -94.3M -18.13% | -115.1M +54.96% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 426.7M -6.77% | 457.7M +102.83% | 225.7M -29.97% | 322.2M +157.23% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -519.14% -99.48% | -99,018.21% +22.19% | -81,035.03% +969.17% | -7,579.23% +181.67% | |
Return on Assets | -41.73% -4.70% | -43.79% -14.75% | -51.37% +26.34% | -40.66% -14.24% | |
Return on Equity | -49.16% +1.40% | -48.48% -14.65% | -56.80% +27.44% | -44.57% -13.64% | |
Revenue Growth | 23,078.81% +603,988.53% | -3.82% -95.36% | -82.28% +104.70% | -40.20% -122.06% | |
Current Ratio | 12.65 -18.00% | 15.43 -15.55% | 18.26 +41.27% | 12.93 -11.92% | |
Cash Ratio | 3.00 +44.41% | 2.08 -46.11% | 3.86 -17.25% | 4.67 +50.39% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow